ASCO 2017: First-Line Addition of Bevacizumab to Endocrine Therapy in Advanced Breast Cancer
To shed more light on data comparing endocrine therapy versus endocrine therapy and bevacizumab in the first-line treatment of women with hormone receptor–positive, HER2-negative advanced breast cancer, researchers analyzed the pooled data from two randomized trials in this patient population: LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance). Miguel Martin, MD, of the Hospital Gregorio Maranon, Universidad Complutense, Madrid, Spain, shared these findings in a poster session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 1012).
A total of 749 patients with advanced breast cancer who received endocrine therapy with or without bevacizumab in either of these trials were included in the analysis. The majority of patients (673) had received letrozole, with 39 patients receiving tamoxifen and 37 patients receiving fulvestrant.
The investigators found that those who received endocrine therapy plus bevacizumab had a longer median progression-free survival than those who received endocrine therapy alone (19 vs. 14.3 months). However, there did not appear to be a survival advantage with the combination therapy, with overall survival rates being similar between the groups. Grade 3–5 hypertension was reported in about 20% of those treated with the combination therapy.
